Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures

Author(s): Manxue Fu, Liling Tang*.

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 14 , Issue 1 , 2019

Submit Manuscript
Submit Proposal


Background: Chimeric Antigen Receptor (CAR) T cell immunotherapy, as an innovative method for tumor immunotherapy, acquires unprecedented clinical outcomes. Genetic modification not only provides T cells with the antigen-binding function but also endows T cells with better immunological functions both in solid and hematological cancer. However, the CAR T cell therapy is not perfect because of several reasons, such as tumor immune microenvironment, and autologous limiting factors of CAR T cells. Moreover, the safety of CAR T cells should be improved.

Objective: Recently many patents and publications have reported the importance of CAR T cell immunotherapy. Based on the patents about CAR T cell immunotherapy, we conclude some methods for designing the CAR which can provide information to readers.

Methods: In this review, we collect recent patents and publications, summarize some specific antigens for oncotherapy from patents and enumerate some approaches to conquering immunosuppression and reinforcing the immune response of CAR T cells. We also sum up some strategies for improving the safety of CAR T cell immunotherapy.

Results: CAR T cell immunotherapy as a neotype cellular immunotherapy has been proved effective in oncotherapy and authorized by FDA. Improvements in CAR designing enhance functions of CAR T cells.

Conclusion: This review, summarizing antigens and approaches to overcome defects of CAR T cell immunotherapy from patents and publications, might contribute to a broad readership.

Keywords: Antigen, CAR T cells, efficiency, immune checkpoints, immune therapy, safety.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [60 - 69]
Pages: 10
DOI: 10.2174/1574892814666190111120908

Article Metrics

PDF: 37